Moleculin Biotech Misses Fiscal Q2 EPS
Moleculin Biotech (NASDAQ:MBRX), a clinical-stage pharmaceutical developer focused on oncology, released its second quarter 2025 results on August 13, 2025.
The biggest news from this update was a GAAP net loss of $(7.6) million.
Reported GAAP EPS of $(0.49) missed the analyst estimate of $(0.40), falling short by $0.09 or 22.3%. As expected, there was no revenue. The overall quarter brought expanded clinical activity and important regulatory developments, but it also highlighted the company’s growing reliance on external funding and balance sheet pressures.
Source Fool.com
